Bio
Associate Professor Shahneen Sandhu is a Consultant Medical Oncologist and a Researcher in the Melanoma and Uro-oncology units at the Peter MacCallum Cancer Centre in Melbourne,…
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221276.
Preprint291 days agoPhase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma
Eva Muñoz‐Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long, Miguel F. Sanmamed, Anna Spreafico, Elizabeth I. Buchbinder, Mario Sznol, Hans Prenen, А. А. Феденко, Mohammed Milhem, Ana Arance, Jean‐Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Nicole Alice Martin, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Anton Kraxner, Nino Keshelava, Oliver Bechter (2025). Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma. , DOI: https://doi.org/10.1158/2767-9764.crc-24-0601.
Article291 days agoTable 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Table 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221270.
Preprint291 days agoAbstract PR005: CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition
Mitchell G. Lawrence, Laura H. Porter, Nicholas Choo, Elaine Sanij, Renea A. Taylor, Richard B. Pearson, Kaylene J. Simpson, Ross D. Hannan, Shahneen Sandhu, Luc Furic (2024). Abstract PR005: CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition. , 23(6_Supplement), DOI: https://doi.org/10.1158/1538-8514.synthleth24-pr005.
Article291 days agoData from CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition
Mitchell G. Lawrence, Laura H. Porter, Nicholas Choo, David Pook, Jeremy Grummet, Carmel Pezaro, Shahneen Sandhu, Susanne Ramm, Jennii Luu, Andrew Bakshi, David L. Goode, Elaine Sanij, Richard B. Pearson, Ross D. Hannan, Kaylene J. Simpson, Renea A. Taylor, Gail P. Risbridger, Luc Furic (2023). Data from CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition. , DOI: https://doi.org/10.1158/1535-7163.c.6543495.v1.
Preprint291 days ago